Phase 3 studies showed zasocitinib, a highly selective oral tyrosine kinase 2 inhibitor, provided rapid, durable skin improvement.
1hon MSN
US, Israel and Iran agree to a 2-week ceasefire but much remains unclear and some attacks continue
TEHRAN, Iran (AP) - Iran, the United States and Israel agreed to a two-week ceasefire, an 11th-hour deal that headed off U.S.
Two Phase 3 clinical studies evaluated the efficacy and safety of zasocitinib in patients with moderate to severe plaque psoriasis and found promising results. Approximately 70% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results